2. Academic Validation
  3. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

  • Nat Chem Biol. 2015 Nov;11(11):878-86. doi: 10.1038/nchembio.1930.
Ujunwa C Okoye-Okafor 1,  Boris Bartholdy 1,  Jessy Cartier 1,  Enoch N Gao 2,  Beth Pietrak 2,  Alan R Rendina 2,  Cynthia Rominger 3,  Chad Quinn 2,  Angela Smallwood 2,  Kenneth J Wiggall 3,  Alexander J Reif 3,  Stanley J Schmidt 3,  Hongwei Qi 2,  Huizhen Zhao 2,  Gerard Joberty 4,  Maria Faelth-Savitski 2,  Marcus Bantscheff 4,  Gerard Drewes 4,  Chaya Duraiswami 2,  Pat Brady 2,  Arthur Groy 2,  Swathi-Rao Narayanagari 1,  Iléana Antony-Debre 1,  Kelly Mitchell 1,  Heng Rui Wang 1,  Yun-Ruei Kao 1,  Maximilian Christopeit 5,  Luis Carvajal 1,  Laura Barreyro 1,  Elisabeth Paietta 6,  Hideki Makishima 7,  Britta Will 1,  Nestor Concha 2,  Nicholas D Adams 3,  Benjamin Schwartz 2,  Michael T McCabe 3,  Jaroslav Maciejewski 7,  Amit Verma 6 8 9 10,  Ulrich Steidl 1 6 9 10
Affiliations

Affiliations

  • 1 Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • 2 Department of Molecular Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • 3 Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • 4 Cellzome, Heidelberg, Germany.
  • 5 Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany.
  • 6 Division of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, New York, USA.
  • 7 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • 8 Department of Developmental &Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • 9 Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • 10 Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, New York, USA.
PMID: 26436839 DOI: 10.1038/nchembio.1930
Abstract

Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are driver mutations in acute myeloid leukemia (AML) and Other cancers. We report the development of new allosteric inhibitors of mutant IDH1. Crystallographic and biochemical results demonstrated that compounds of this chemical series bind to an allosteric site and lock the Enzyme in a catalytically inactive conformation, thereby enabling inhibition of different clinically relevant IDH1 mutants. Treatment of IDH1 mutant primary AML cells uniformly led to a decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells, in vitro and in vivo. Molecularly, treatment with the inhibitors led to a reversal of the DNA cytosine hypermethylation patterns caused by mutant IDH1 in the cells of individuals with AML. Our study provides proof of concept for the molecular and biological activity of novel allosteric inhibitors for targeting different mutant forms of IDH1 in leukemia.

Figures
Products